PHXM — Phaxiam Therapeutics SA Income Statement
0.000.00%
Last trade - 00:00- €0.92m
- €12.39m
- €1.33m
Annual income statement for Phaxiam Therapeutics SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 5.28 | 3.72 | 4.18 | 6.65 | 1.33 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 69.4 | 72.5 | 60.7 | 9.44 | 25 |
| Operating Profit | -64.1 | -68.8 | -56.5 | -2.8 | -23.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -62.7 | -73.3 | -53.8 | 0.293 | -23.7 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -62.7 | -73.3 | -53.8 | -0.228 | -23.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -62.7 | -73.3 | -53.8 | -0.228 | -23.5 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -62.7 | -73.3 | -53.8 | -0.228 | -23.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -32.3 | -36.8 | -21 | -4.45 | -4.68 |
| Dividends per Share |